Study: Pfizer drug lowers risk of breast cancer
Millions of women at high risk of breast cancer because of genes, family history or other reasons have a new option for preventing the disease.
A big study finds that a drug cut the risk of developing breast cancer by more than half in women who were past menopause. The drug is exemestane, sold by Pfizer Inc. as Aromasin and in generic form.
Two drugs are already available for preventing breast cancer - tamoxifen and raloxifene. But these are unpopular because they can cause blood clots and uterine cancer. The study did not find these side effects with the newer drug.
Results were discussed Saturday at a cancer conference in Chicago and published in the New England Journal of Medicine.